Video: Regenerative Medicine and collaboration at the Utrecht Science Park
16 april 2019

All experts in the field of regenerative medicine and stem cell research are situated on one location at the Utrecht Science Park, in the Regenerative Medicine Center Utrecht (RMCU). Regenerative medicine is a promising field of interest, where scientists do research with the aim to restore the structure and function of damaged tissue and organs.

Genmab and Merus are cooperating with Kadans Science Partner as developer for “The Accelerator” on Utrecht Science Park.
10 april 2019

Biotechnology companies Genmab and Merus are cooperating with Kadans Science Partner as developer for “The Accelerator”, a new multi-tenant Life Sciences building on Utrecht Science Park.

Board members from UU, HU and Foundation USP plant a tree
5 april 2019

This week, Annetje Ottow (Vice President of UU’s Executive Board), Tineke Zweed (Executive Boards HU), Jan Henk van der Velden (Stichting Utrecht Science Park) and Fiona van ‘t Hullenaar (Director Real Estate and Campus) took the initiative of planting a tree next to the Bolognalaan cycling path.

Micreos Raises €30 Million for Endolysin Technology Set to Replace Antibiotics
29 maart 2019

Dutch biotechnology company Micreos announced it has secured €30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its breakthrough OTC Gladskin product for eczema.

Video about the Utrecht Exposome Hub
28 maart 2019

Utrecht Science Park is the largest science park in the Netherlands. Together we are working on innovative solutions for societal issues such as a longer, healthier life and sustainability. A good example is the collaboration in the Utrecht Exposome Hub.

Hubrecht Organoid Technology and CrownBio Announce a Strategic Partnership
27 maart 2019

Hubrecht Organoid Technology and CrownBio Announce a Strategic Partnership on Oncology Organoid-Based Preclinical Drug Development and Validation Services

Synerkine Pharma raises 3.3 million euro in series a financing
25 maart 2019

Synerkine Pharma B.V., which develops fusion proteins for the treatment of chronic pain, announced today that it successfully closed a EUR 3.3 million Series A financing from Thuja Capital, an undisclosed private investor, and the company’s founders.